scholarly journals T-Cell Engraftment Kinetics Following Myeloablative and Nonmyeloablative Regimens for Allogeneic Hematopoietic Transplantation

2009 ◽  
Vol 15 (2) ◽  
pp. 102
Author(s):  
D. Mickelson ◽  
L. Sproat ◽  
R. Dean ◽  
R. Sobecks ◽  
L. Rybicki ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Engraftment ◽  
Hematopoietic Transplantation ◽  
Allogeneic Hematopoietic Transplantation

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas

2001 ◽  
Vol 19 (17) ◽  
pp. 3766-3770 ◽  
Author(s):  
Jose Rodriguez ◽  
Mark Munsell ◽  
Salim Yazji ◽  
Fredrick B. Hagemeister ◽  
Anas Younes ◽  
...  
Keyword(s):  
Survival Rate ◽  
T Cell ◽  
B Cell ◽  
High Dose Chemotherapy ◽  
Serum Lactate Dehydrogenase ◽  
Published Data ◽  
High Dose ◽  
Conventional Chemotherapy ◽  
Hematopoietic Transplantation ◽  
Allogeneic Hematopoietic Transplantation

PURPOSE: To evaluate the outcome of high-dose chemotherapy (HDCT) and autologous or allogeneic hematopoietic transplantation in patients with peripheral T-cell lymphoma (PTCL) who experienced disease recurrence after prior conventional chemotherapy. PATIENTS AND METHODS: We performed a retrospective analysis of 36 PTCL patients from the University of Texas M.D. Anderson Cancer Center treated between 1989 and 1998 with HDCT and autologous or allogeneic hematopoietic transplantation. RESULTS: A total of 36 patients were studied (29 received autologous transplantation, and seven received allogeneic transplantation). The overall survival rate at 3 years was 36% (95% confidence interval [CI], 23% to 59%), and the progression-free survival (PFS) rate was 28% (95% CI, 16% to 49%). The pretransplant serum lactate dehydrogenase level was the most important prognostic factor for both survival and PFS rates (P < .001). A Pretransplant International Prognostic Index score of ≤ 1 indicated a superior survival rate (P = .036) but not an improved PFS rate. A median follow-up of 43 months (range, 13 to 126 months) showed 13 patients (36%) were still alive with no evidence of disease. CONCLUSION: Our results are comparable to the published data on HDCT in B-cell non-Hodgkin’s lymphoma (NHL) patients despite the fact that patients with PTCL are known to have a worse outcome compared with B-cell NHL patients. Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation.

scholarly journals Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation

2018 ◽  
Vol 201 (11) ◽  
pp. 3443-3455 ◽  
Author(s):  
Tomomi Toubai ◽  
Hiroya Tamaki ◽  
Daniel C. Peltier ◽  
Corinne Rossi ◽  
Katherine Oravecz-Wilson ◽  
...  
Keyword(s):  
T Cell ◽  
T Cell Responses ◽  
Cell Responses ◽  
Hematopoietic Transplantation ◽  
Allogeneic Hematopoietic Transplantation

scholarly journals Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

2021 ◽  
Author(s):  
Marie Robin ◽  
Raphael Porcher ◽  
Corentin Orvain ◽  
Jacques-Olivier Bay ◽  
Fiorenza Barraco ◽  
...  
Keyword(s):  
Hematopoietic Transplantation ◽  
Allogeneic Hematopoietic Transplantation
Sign in / Sign up

Export Citation Format

Share Document